Article -> Article Details
| Title | Anti-Obesity Drugs Market Size, Trends, Industry Share and Forecast Report 2026-2034 |
|---|---|
| Category | Business --> Healthcare |
| Meta Keywords | Anti-Obesity Drugs Market |
| Owner | akshaykumar |
| Description | |
| Market Overview The global anti-obesity drugs
market was valued at USD 2.7 billion in 2025 and is projected to reach USD
6.4 billion by 2034, with a CAGR of 9.50% during 2026-2034. Growth is driven by
rising obesity rates, increased health awareness, and advancement in drug
development. The market is expanding due to government initiatives, R&D
investment, and the availability of both prescription and over-the-counter
drugs. Study Assumption Years
Anti-Obesity Drugs Market Key Takeaways
Sample Request Link: https://www.imarcgroup.com/anti-obesity-drugs-market/requestsample Market Growth Factors The global market for anti-obesity drugs is on the rise due
to the increasing
prevalence of obesity worldwide, increasing health consciousness amongst the
population, and a growing number of people opting for medical therapy for
weight control. Prescribing appetite-reducing drugs to achieve and maintain
weight loss has now become
common, with the pharmaceutical industry investing heavily in their
development. Pharmaceutical companies are now developing drugs that are safer
and more effective, and have fewer
side effects. Regulatory approvals and government initiatives
for obesity treatments have also supported these efforts. A second factor has been the increased prescribing of GLP-1
receptor agonists such as
semaglutide (Wegovy) and tirzepatide (Zepbound). Clinical studies have shown
that these drugs are more
efficacious for weight-loss compared with customary anti-obesity drugs,
achieving a weight-loss of between 15% and 22% in the first year of treatment.
Supply issues arose as demand grew and prescriptions increased. Further efforts
to improve upon safety profiles and to increase potency through continued
research are expected to sustain the market. Furthermore, expanding insurance coverage and reimbursement
for these products is expected to help drive market growth considerably. As
obesity is recognized as a chronic disease with adverse health consequences,
public and private payers are developing coverage policies for weight loss
drugs. The proportion of US employers with 500 or more employees offering
insurance plans covering weight-loss medications increased from 41% in 2023 to
44% in 2024. US Medicare and commercial insurers' reimbursement coverage for
GLP-1 receptor agonists is expanding. In Europe, the integration of clinical
management of obesity into healthcare systems of various countries improved
access for obese patients to drugs, and in turn, drug sales. Market Segmentation By Drug Class:
By Drug Type:
By Distribution Channel:
Regional Insights North America holds the largest anti-obesity drugs market
share at 36.7% in 2025. The region's market leadership is supported by high
obesity prevalence, advanced healthcare infrastructure, strong government
initiatives, and robust R&D investments by major pharmaceutical players.
Prescription drug availability, reimbursement policies, and increasing
weight-loss medication adoption further consolidate North America's dominant
position. Recent Developments & News
Key Players
If you require any specific information that is not
covered currently within the scope of the report, we will provide the same as a
part of the customization. Request For Customization: https://www.imarcgroup.com/request?type=report&id=5544&flag=E About Us IMARC Group is a global management consulting firm that
helps the world’s most ambitious changemakers to create a lasting impact. The
company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies,
company incorporation assistance, factory setup support, regulatory approvals
and licensing navigation, branding, marketing and sales strategies, competitive
landscape and benchmarking analyses, pricing and cost research, and procurement
research. Contact Us IMARC Group, 134 N 4th St. Brooklyn, NY 11249, USA, Email: sales@imarcgroup.com, Tel No: (D) +91 120 433 0800, United States: +1-201971-6302 | |